In a follow-up study, we assessed the impact of a more frequent dose of CDD866 and everolimus, a new generation, less cytotoxic, molecular-targeted agent, which inhibits the mammalian target of rapamycin (mTOR), on cancer cachexia. This evidence concerns the gene MTOR and cancer.